Relevant bibliographies by topics / Neoadjuvant chemo

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Neoadjuvant chemo'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Neoadjuvant chemo.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Neoadjuvant chemo"

1

Baumann and Köchli. "Primary Systemic Treatment of Invasive Breast Cancer." Swiss Surgery 6, no. 3 (2000): 137–41. http://dx.doi.org/10.1024/1023-9332.6.3.137.

Full text
Abstract:
Die präoperative oder neoadjuvante Chemo- oder Hormontherapie stellt in der Behandlung des lokal fortgeschrittenen Mammakarzinoms eine neue Therapieoption dar. Klinische Studien konnten keinen Unterschied bezüglich des Gesamtüberlebens für Patientinnen zeigen, die mit der konventionellen postoperativen, adjuvanten Therapie und den Patientinnen, die neoadjuvant behandelt wurden. Jedoch wurde durch die präoperative Chemo- und Hormontherapie in vielen Fällen eine deutliche Tumorverkleinerung und damit eine brusterhaltende Therapie erreicht. Die neoadjuvante Chemotherapie ist somit auch ein gutes
APA, Harvard, Vancouver, ISO, and other styles
2

Chiu, Joanne W., Roland Leung, Vikki Tang, et al. "Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy." Postgraduate Medical Journal 95, no. 1121 (2019): 155–61. http://dx.doi.org/10.1136/postgradmedj-2018-135739.

Full text
Abstract:
BackgroundOver the last 10 years, there has been a major treatment revolution for early human epidermal growth factor receptor 2 (HER2)–positive breast cancer. We aimed to explore the outcome of different neoadjuvant chemotherapy in a tertiary breast cancer centre with early HER2-positive breast cancer as well as factors associated with pathological complete response (pCR) and recurrence-free survival (RFS). The pattern of recurrence was also studied.MethodsThis retrospective study analysed the outcome of neoadjuvant chemotherapy during the period 2005 to 2016 in a tertiary referral centre in
APA, Harvard, Vancouver, ISO, and other styles
3

Ghelani, Ghanshyam H., Roger Wong, Stephen L. Graziano, Jeffrey S. Ross, and Alina Basnet. "Comparative survival after neoadjuvant vs adjuvant systemic therapy in resectable stage II and stage III non-small cell lung cancer: A retrospective study using the National Cancer Database." Journal of Clinical Oncology 42, no. 16_suppl (2024): 8075. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.8075.

Full text
Abstract:
8075 Background: Resectable Stage II and III Non-small Cell Lung Cancer (NSCLC) are managed with surgery and perioperative systemic therapy [Chemo/Chemo-Immunotherapy (IO)]. However, there lacks a consensus in optimal selection between neoadjuvant and adjuvant approaches. Hence, it underscores the necessity to undertake a comparative survival outcome associated with systemic therapy in these distinct settings. Methods: We conducted an analysis, of individuals aged 18 and above diagnosed with stage II and stage III NSCLC between 2004 - 2020, using data from the National Cancer Database (NCDB).
APA, Harvard, Vancouver, ISO, and other styles
4

Téoule, Patrick, Jörg Trojan, Wolf Bechstein, and Guido Woeste. "Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer." Digestive Surgery 32, no. 4 (2015): 229–37. http://dx.doi.org/10.1159/000381884.

Full text
Abstract:
Background/Aims: Patients with locally advanced gastric cancer benefit from neoadjuvant chemotherapy. Potential disadvantages of neoadjuvant chemotherapy include increased surgical complications, leading to increased postoperative morbidity. Methods: We retrospectively studied medical records of 135 patients with resectable cancer of the stomach who underwent gastrectomy between 2002 and 2009. The impact of neoadjuvant chemotherapy on postoperative morbidity was investigated. We compared demographic, clinical and operative data, morbidity and mortality from 105 patients who received surgical t
APA, Harvard, Vancouver, ISO, and other styles
5

Siefker-Radtke, Arlene O., Gary D. Steinberg, Jens Bedke, et al. "Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866." Journal of Clinical Oncology 38, no. 6_suppl (2020): TPS599. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.tps599.

Full text
Abstract:
TPS599 Background: MIBC prognosis is poor, despite standard neoadjuvant cisplatin-based chemo. PD-1/PD-L1 pathway inhibition is an effective first-line option for cisplatin-ineligible pts and a second-line option for platinum-based chemo pretreated pts. Neoadjuvant chemo + pembro, a PD-1 inhibitor, recently showed encouraging pathologic complete response rates, in cisplatin-eligible patients with MIBC (NCT02365766), warranting further investigation. Methods: KEYNOTE-866 (NCT03924856) is a randomized phase 3 study to assess efficacy and safety of chemo+perioperative pembro versus chemo+perioper
APA, Harvard, Vancouver, ISO, and other styles
6

Spicer, Jonathan, Nicolas Girard, Mariano Provencio, et al. "Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816." Journal of Clinical Oncology 42, no. 17_suppl (2024): LBA8010. http://dx.doi.org/10.1200/jco.2024.42.17_suppl.lba8010.

Full text
Abstract:
LBA8010 Background: The phase 3 CheckMate 816 study established neoadjuvant NIVO + chemo as a standard of care for eligible pts with resectable NSCLC. Here, we report the 4-year survival update from this study, representing the longest follow-up among all global phase 3 studies evaluating neoadjuvant or perioperative immunotherapy-based treatments. Methods: Adults with stage IB (≥ 4 cm)–IIIA (per AJCC v7) resectable NSCLC, ECOG PS ≤ 1, and no known EGFR/ ALK alterations were randomized 1:1 to receive NIVO 360 mg + chemo Q3W or chemo alone Q3W for 3 cycles, followed by surgery. Event-free survi
APA, Harvard, Vancouver, ISO, and other styles
7

Jiang, Bo, Xin Yang, Pengyi Yu, et al. "Treg cells and the response to neoadjuvant chemotherapy combined with immunotherapy in resectable esophageal squamous carcinoma." Journal of Clinical Oncology 41, no. 16_suppl (2023): e14626-e14626. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e14626.

Full text
Abstract:
e14626 Background: More and more studies focus on the neoadjuvant chemotherapy combined with immunotherapy (chemo-immunotherapy) in resectable esophageal squamous carcinoma (ESCC). Herein, we aimed to evaluate the efficacy and safety of neoadjuvant programmed cell death protein 1 inhibitors with chemotherapy and explore tumor microenvironment (TME) profiles. Methods: Patients with previously untreated, resectable, stage III ESCC in the third affiliated hospital of Soochow University were enrolled. Each patient received two-four cycles of neoadjuvant chemo-immunotherapy before surgical resectio
APA, Harvard, Vancouver, ISO, and other styles
8

Chen, Yilin, Lu Yang, Yuhong Huang, et al. "Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer." Journal for ImmunoTherapy of Cancer 13, no. 4 (2025): e010365. https://doi.org/10.1136/jitc-2024-010365.

Full text
Abstract:
BackgroundNeoadjuvant immunotherapy combined with chemotherapy (Chemo-IM) is associated with significantly improved pathological complete response (pCR) rates and long-term survival outcomes in patient with early-stage triple-negative breast cancer (TNBC). However, only a small proportion of patients benefit from the addition of immunotherapy. Here, we explored and confirmed the role of intratumoral microbiota in screening patients with TNBC who are likely to benefit from neoadjuvant Chemo-IM.MethodsPatients with previously untreated, non-metastatic TNBC receiving neoadjuvant Chemo-IM were enr
APA, Harvard, Vancouver, ISO, and other styles
9

Wang, Changli, Ke-Neng Chen, Qixun Chen, et al. "Abstract CT081: Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816." Cancer Research 83, no. 8_Supplement (2023): CT081. http://dx.doi.org/10.1158/1538-7445.am2023-ct081.

Full text
Abstract:
Abstract Background: In the global, randomized phase 3 CheckMate 816 study (NCT02998528), neoadjuvant NIVO + chemo demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and pathologic complete response (pCR) vs chemo in pts with resectable NSCLC. Here, we report results from the Chinese subgroup of this study. Methods: Adults with stage IB (≥ 4 cm)-IIIA (per AJCC 7th edition) resectable NSCLC, ECOG PS ≤ 1, and no known EGFR/ALK mutations were randomized to NIVO 360 mg + chemo Q3W or chemo Q3W for 3 cycles followed by surgery. EFS and pCR (pe
APA, Harvard, Vancouver, ISO, and other styles
10

Malapati, Sindhu Janarthanam, Sunny R. K. Singh, Rohit Kumar, and Tarik H. Hadid. "Neoadjuvant treatment with chemotherapy or chemoradiation in stage III non-small cell lung cancer: Analysis of the National Cancer Database." Journal of Clinical Oncology 38, no. 15_suppl (2020): 7046. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.7046.

Full text
Abstract:
7046 Background: Use of neoadjuvant chemotherapy (Neo-chemo) improves survival in locally advanced NSCLC. However, data regarding the benefit of adding radiation (Neo-CRT) is limited. Meta-analyses suggest that the use of Neo-CRT could lead to significant tumor downstaging but with increase in therapy-related mortality. Methods: Patients with resected stage III NSCLC were identified from the NCDB between 2010 and 2015. Patients were divided into two groups based on the type of neoadjuvant therapy received (Neo-chemo vs. Neo-CRT). Surgical and survival outcomes were compared. Kaplan-Meier metho
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Neoadjuvant chemo"

1

Filitto, Giuseppe. "Implementation of an automated pipeline to predict the response to neoadjuvant chemo-radiotherapy of patients affected by colorectal cancer." Master's thesis, Alma Mater Studiorum - Università di Bologna, 2021. http://amslaurea.unibo.it/24832/.

Full text
Abstract:
Colorectal cancer is a malignant neoplasm of the large intestine resulting from the uncontrolled proliferation of one of the cells making up the colorectal tract. In order to get information about diagnosis, therapy evaluation on colorectal cancer, analysis on radiological images can be performed through the application of dedicated algorithms. Up to now, this process is performed using manual or semi-automatic techniques, which are time-consuming and highly operator dependent. The aim of this project is to develop and apply an automated pipeline to predict the response to neoadjuvant chem
APA, Harvard, Vancouver, ISO, and other styles
2

Matta, Célia. "Neuropathies induites par chimiothérapie néo-adjuvante du cancer du sein : atteintes périphériques et centrales, mécanismes impliqués et perspectives thérapeutiques." Thesis, Strasbourg, 2018. http://www.theses.fr/2018STRAJ080/document.

Full text
Abstract:
La chimiothérapie néoadjuvante (CNA) est une avancée majeure dans les traitements des cancers du sein. La CNA réduit nettement la tumeur primaire et permet une chirurgie conservatrice à tous les stades du cancer. Malheureusement, elle s’accompagne de dysfonctionnements neurologiques qui limitent le succès du traitement anti-tumoral. La prise en charge médicale de ces troubles neurologiques est problématique compte tenu de l’inefficacité des neuroprotecteurs disponibles. De plus, la recherche de nouvelles thérapeutiques est handicapée par l’absence de modèles expérimentaux reproduisant fidèleme
APA, Harvard, Vancouver, ISO, and other styles
3

Hultman, Bo. "Clinical and Experimental Studies in Peritoneal Metastases from Gastric Cancer." Doctoral thesis, Uppsala universitet, Kolorektalkirurgi, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-197776.

Full text
Abstract:
Gastric cancer (GC) is one of leading causes of death in the world, and peritoneal metastases (PM) are a major site of recurrence. PM from GC implies a poor prognosis, with median overall survival (mOS) approximately 3 months and no survival at five years. The aims of this thesis were to explore the incidence and evaluate prognostic factors for mOS of PM from GC in a defined population; to investigate the outcome of a new multimodal treatment; to analyse the treatment costs, and to investigate differences in drug sensitivity between individual patient samples and between various tumours. The i
APA, Harvard, Vancouver, ISO, and other styles
4

Zucha, Josef [Verfasser], Stefan [Akademischer Betreuer] Plontke, Sabrina [Akademischer Betreuer] Kösling, and Kerstin [Akademischer Betreuer] Lorenz. "Die definitive und neoadjuvante Radio(chemo)therapie des Ösophaguskarzinoms / Josef Zucha. Betreuer: Stefan Plontke ; Sabrina Kösling ; Kerstin Lorenz." Halle, Saale : Universitäts- und Landesbibliothek Sachsen-Anhalt, 2015. http://d-nb.info/1080171029/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Türk, Leonie. "Mikrosatelliteninstabilität (MSI) in Rektumkarzinomen vor und nach Chemoradiotherapie." Doctoral thesis, 2012. http://hdl.handle.net/11858/00-1735-0000-000D-EFB3-B.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Neoadjuvant chemo"

1

Dietz, Andreas, and Jan B. Vermorken. "Is Reducing the Extent of Local Treatments Justified After Successful Neoadjuvant Therapy?" In Critical Issues in Head and Neck Oncology. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-031-84539-0_17.

Full text
Abstract:
Abstract One of the main goals of neoadjuvant (induction) therapy before surgery ± adjuvant treatment in head and neck cancer is to downsize the disease and to reduce the need for further aggressive adjuvant treatment. A classic example for this strategy has been shown for larynx preservation treatment by using cisplatin/5-fluorouracil (PF) induction chemotherapy in advanced laryngeal and hypopharyngeal cancer. Currently, the benefit for the individual patient with an indication for total laryngectomy would only be given if the tumor responds well to induction therapy and the larynx can be pre
APA, Harvard, Vancouver, ISO, and other styles
2

von Weyhern, Claus Hann, and Björn L. D. M. Brücher. "Application of Laser Microdissection and Quantitative PCR to Assess the Response of Esophageal Cancer to Neoadjuvant Chemo-Radiotherapy." In Methods in Molecular Biology. Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-163-5_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kheng-Seong, Ng, and Michael J. Solomon. "Neoadjuvant (Chemo)Radiotherapy with Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients with Low cT3/4 Rectal Cancer." In 50 Landmark Papers every Colorectal Surgeon Should Know. CRC Press, 2024. http://dx.doi.org/10.1201/9780429285714-16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ajithkumar, Thankamma. "Gastrointestinal tumours." In Radiotherapy Planning. Oxford University PressOxford, 2023. http://dx.doi.org/10.1093/med/9780198722694.003.0009.

Full text
Abstract:
Abstract The role of radiotherapy for gastrointestinal cancers depends on the site of the primary tumour and the stage of disease. There is global variation in the management of gastrointestinal cancers. For example, locally advanced operable oesophageal cancers are treated with neoadjuvant chemotherapy followed by surgery in the UK whereas it is treated with neoadjuvant chemo-radiotherapy in Europe and the US. This chapter discusses the clinical and imaging features of cancers occurring in different parts of the gastrointestinal tract, the role of radiotherapy for tumours arising in different
APA, Harvard, Vancouver, ISO, and other styles
5

De Stefano, Francesca, Gianfrancesco Intini, Giulia Costantini, Carlo Gennaro, Ali Chahrour, and Igor Monsellato. "Robotic Rectal Resection for Rectal Cancer: State of the Art." In Recent Understanding of Colorectal Cancer Treatment. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.106199.

Full text
Abstract:
Surgical resection with total mesorectal excision (TME) represents a crucial milestone in the treatment of rectal cancer. Conventional open procedures have been gradually replaced by minimally invasive techniques. To date, laparoscopic and robotic resection associated with neoadjuvant chemo-radiotherapy, represent the gold standard for rectal malignancies. Robotic surgery, when performed by an experienced surgeon, can offer advantages in case of difficult anatomical conditions, such as in male patients with a narrow pelvis. Higher costs remain a matter of debate in the diffusion of robotic pla
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Neoadjuvant chemo"

1

Živković Radojević, Marija, Neda Milosavljević, Slađana Aćimović Talijan, Tatjana B. Miladinović, Aleksandar Miladinović, and Miloš Grujić. "Challenges in radiotherapy planning in patients with synchronous rectal and prostate cancer and hip prosthesis." In 2nd International Conference on Chemo and Bioinformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.209zr.

Full text
Abstract:
Background. Prostate and rectal carcinomas, although among the most common malignancies in males, rarely exhibit synchronous diagnosis and treatment of both malignancies. This paper presents a case of a patient with synchronous prostate and rectal carcinoma and an artificial right hip, which complicates the creation of a radiotherapy plan. Case Report. A 76-year-old male was diagnosed with synchronous mucinous infiltrating adenocarcinoma of the rectum (T3N0M0) and adenocarcinoma of the prostate (T3aN0M0), confirmed by immunohistochemistry. He had a history of testicular carcinoma previously tr
APA, Harvard, Vancouver, ISO, and other styles
2

Abdujapparov, A., S. Tkachev, and F. Djuraev. "PO-108 Nonstandard hypofraction radiotherapy in neoadjuvant chemo-radiation therapy in treatment of locally advanced rectal cancer." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.633.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Boesch, Maximilian, Florent Baty, Sacha Rothschild, et al. "Characterizing the tumor microbiome of non-small cell lung cancer patients receiving neoadjuvant chemo-immunotherapy (SAKK 16/14)." In ERS Congress 2024 abstracts. European Respiratory Society, 2024. http://dx.doi.org/10.1183/13993003.congress-2024.oa1092.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Singh, S., V. Goel, V. Talwar, et al. "Neo-adjuvant chemotherapy followed by surgery versus definitive chemo radiation as treatment for localized carcinoma cervix." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685273.

Full text
Abstract:
Background: Cervical cancer is ranked as the most common cancer in Indian women, second most common cancer worldwide and the leading cause of death in the developing countries. In the developing countries majority of the patients are diagnosed at locally advanced stages. The standard treatment of locally advanced cervical cancer is concomitant chemoradiation (CTRT) using platinum based chemotherapy. However, some randomized studies have shown improved results for patients receiving neoadjuvant chemotherapy (NACT) followed by surgical resection in comparison to patient receiving radiation alone
APA, Harvard, Vancouver, ISO, and other styles
5

Forde, Patrick M., Jonathan Spicer, Shun Lu, et al. "Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-ct003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wolfgang Beckabir, AB, Alec Wilkinson, Mark Woodcock, et al. "560 Molecular and immunogenomics features associated with complete response and survival after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0560.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Shaw, RJ, F. Lara, CD Robles, and D. Vilar. "P3-13-08: Survival Analysis and Recurrence Patterns in Locally Advanced Breast Cancer Following Neoadjuvant Chemotherapy and Preoperative Concurrent Chemo Radiotherapy." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-p3-13-08.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Brianese, Rafael Canfield, Giovana Tardin Torrezan, Marina de Brot Andrade, et al. "INVESTIGATION OF CIRCULATING TUMOR DNA (CTDNA) IN PATIENTS WITH NON-METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC) SUBMITTED TO NEOADJUVANT CHEMOTHERAPY." In Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2015.

Full text
Abstract:
Objective: Loss-of-function germline mutation in BRCA1 increases breast cancer risk, especially in the triple-negative breast cancer (TNBC) subtype. BRCA1 impairment may confer benefit from the treatment with DNA damage-inducing drugs and PARP1 inhibitors. Patients who respond to neoadjuvant chemotherapy tend to have good outcomes. The aim of this study was to characterize the resistance to chemotherapy in patients with germline-characterized TNBC by investigating somatic mutations in ctDNA. Methods: Germline genetic testing was done using cancer-predisposing gene panels (26–126 genes) to clas
APA, Harvard, Vancouver, ISO, and other styles
9

Gomez-Wolff, R., H. Garcia, and C. Ossa. "Abstract P5-16-20: Impact of “immunohistochemistry-based molecular subtype” on chemo-sensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy (NAC)." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p5-16-20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Avallone, Antonio, Elena Di Gennaro, Paolo Delrio, et al. "Abstract LB-219: Neoadjuvant multidisciplinary phase II study (BRANCH) of an early bevacizumab schedule plus chemo-radiation therapy in rectal cancer: efficacy, safety, and biomarkers." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-lb-219.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Neoadjuvant chemo' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography